More patients in the WT KRAS group had eye toxicities compared with the MT group (45% vs. 29%) whereas more patients with MT KRAS tumours experienced hair (31% vs. 51%) and nail (29% vs. 37%) toxicities. The gene discussed is KRAS; the disease is neoplasm.